ReviewCurrent drug targets2011
Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery.
Review in Current drug targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Cyanobacterial Biofactories Beyond Model Strains: Exploratory Screening of Immunomodulatory Activity inPlants (Basel, Switzerland) · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Genetic and biochemical diversity of terpene biosynthesis in cyanobacterial strains from tropical soda lakes.Frontiers in microbiology · 2025Article
- Sulfated Aeruginosins from Lake Kinneret:Marine drugs · 2024Article
- Article
- Optimizing Luminous Transmittance of a Three-Dimensional-Printed Fixed Bed Photobioreactor.3D printing and additive manufacturing · 2024Article
- Non-Canonical Amino Acids as Building Blocks for Peptidomimetics: Structure, Function, and Applications.Biomolecules · 2023Review
- Cyanotoxins and Other Bioactive Compounds from the Pasteur Cultures of Cyanobacteria (PCC).Toxins · 2023Review
- Metabolomics Applied to Cyanobacterial Toxins and Natural Products.Advances in experimental medicine and biology · 2023Review
- The effects of secondary bacterial metabolites on photosynthesis in microalgae cells.Biophysical reviews · 2022Review
- Influence of wettability and surface design on the adhesion of terrestrial cyanobacteria to additive manufactured biocarriers.Bioprocess and biosystems engineering · 2022Article
- Discovery of Anticancer Agents of Diverse Natural Origin.Journal of natural products · 2022Article
- Cyanobacteria and microalgae bioactive compounds in skin-ageing: potential to restore extracellular matrix filling and overcome hyperpigmentation.Journal of enzyme inhibition and medicinal chemistry · 2021Review
- Phytoplankton of the Curonian Lagoon as a New Interesting Source for Bioactive Natural Products. Special Impact on Cyanobacterial Metabolites.Biomolecules · 2021Article
- Symbioses of Cyanobacteria in Marine Environments: Ecological Insights and Biotechnological Perspectives.Marine drugs · 2021Review
- The need to innovate sample collection and library generation in microbial drug discovery: a focus on academia.Natural product reports · 2021Article
- Eighteen New Aeruginosamide Variants Produced by the Baltic CyanobacteriumMarine drugs · 2020Article
- Targeting eukaryotic proteases for natural products-based drug development.Natural product reports · 2020Review
- The Effects of Cyanobacterial Bloom Extracts on the Biomass, Chl-a, MC and Other Oligopeptides Contents in a NaturalInternational journal of environmental research and public health · 2020Article
- Combined Danio rerio embryo morbidity, mortality and photomotor response assay: A tool for developmental risk assessment from chronic cyanoHAB exposure.The Science of the total environment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cyanobacteria are considered a promising source for new pharmaceutical lead compounds and a large number of chemically diverse and bioactive metabolites have been obtained from cyanobacteria over the last few decades. This review highlights the structural diversity of natural products from freshwater and terrestrial cyanobacteria. The review is divided into three areas: cytotoxic metabolites, protease inhibitors, and antimicrobial metabolites. The first section discusses the potent cytotoxins cryptophycin and tolytoxin. The second section covers protease inhibitors from freshwater and terrestrial cyanobacteria and is divided in five subsections according to structural class: aeruginosins, cyanopeptolins, microviridins, anabaenopeptins, and microginins. Structure activity relationships are discussed within each protease inhibitor class. The third section, antimicrobial metabolites from freshwater and terrestrial cyanobacteria, is divided by chemical class in three subsections: alkaloids, peptides and terpenoids. These examples emphasize the structural diversity and drug development potential of natural products from freshwater and terrestrial cyanobacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.